Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

✍ Scribed by Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Bueschen; John R. Neefe; Robert C. Flanigan

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 289 KB
• Volume: 74
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19940801)74:3<916::aid-cncr2820740319>3.0.co;2-z

✦ Synopsis

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology Group undertook a Phase I1 trial of low dose, continuous 5-FU in metastatic renal cell cancer.

Methods. Sixty-one patients were entered in the study to receive 300 mg 5-FU/m2/day for 7 days via a central venous catheter and external programmable pump. The pump was refilled every 7 days. Pyridoxine (50 mg, orally) was administered prophylactically three times a day.

Results. A response of 5.2% (one complete response [CR] and two partial responses [PRs]) was achieved. The overall survival was 12 months. The duration of the CR is more than 30 months. Both PRs lasted 6 months. No